United states - Events
Innovating Novel Combination Therapies and Maximising Preclinical and Clinical Development to Improve Glioblastoma Targeting and Increase Investment Opportunities to Ultimately Bring Efficacious Therapies to Patients in NeedThe glioblastoma drug development space has been energized by Merck's acquisition of Modifi Bio last December. This landmark deal has sparked renewed hope in a field long challenged by limited investment and clinical breakthroughs.
Looking ahead to 2026, it's crucial to sustain this momentum. The 7th Glioblastoma Drug Development Summit is your essential platform for accelerating new treatments and continuing this vital progress.
Join us for a definitive, 3-day summit designed to accelerate progress. With groundbreaking content and six deep-dive workshops, you'll connec…
The 20th Clinical Research Billing Compliance Summit brings together compliance officers, billing specialists, and research leaders to share strategies, updates, and best practices for accurate, audit-ready billing. Learn from experts, join workshops, and network with peers February 23-25, 2026 in New Orleans.
Category: Conferences | Science, Health and Medicine | Pharmaceuticals | Clinical
Date and Time: 23rd February 2026 at 9:00 am to 25th February 2026 at 5:00 pm
Venue details: New Orleans Marriott Warehouse Arts District, 859 Convention Center Boulevard, New Orleans, Louisiana, 70130, United States
Uniting 100+ leaders from cutting-edge biotechs to global pharma, this summit delivers comprehensive insight across antigen selection, biomarker strategy, B-cell and cellular tolerance mechanisms, delivery platforms, and clinical trial execution.
The 2026 agenda spotlights late-stage data from Topas, Diamyd, and COUR; novel mRNA- LNP approaches from Moderna; integrated nanotherapeutics; and next-generation Treg and tolerance-restoring strategies. Key sessions explore central versus peripheral tolerance, and how gene and cell therapy are redefining therapeutic durability and safety.
Now in its ninth year, the 9th Antigen-Specific Immune Tolerance Summit remains the only end-to-end meeting dedicated to advancing antigen-specific immune tolerance. Join Pfizer, Moderna, AbbVie, Diamyd, COUR, a…
Event Overview
Discover the breakthroughs shaping the future of medicine at this two-day event designed for scientists, innovators, and industry leaders. Our programme combines cutting-edge talks, interactive panel discussions, and dedicated networking opportunities to foster collaboration and spark new ideas:
Gene Therapies for Neurological & Neurometabolic Disorders: Explore the full translational journey – from preclinical innovation to clinical trials – featuring a unique perspective from a parent whose child received gene therapy.
Making New Medicines for Sensory Disorders: Learn how advanced modalities are transforming treatment for vision loss, hearing impairment, and neuropathic pain, and tackle the challenges of adoption and reimbursement.
Individually Rare but Collectively C…
SAE Media Group's AI in Drug Discovery 2026 takes place 9–10 March in London. Join pharma and biotech leaders to explore how AI, ML, and generative tools are transforming drug pipelines. The agenda features case studies, clinical updates, and expert panels on target ID, computational design, and scaling AI across R and D. Discover the latest breakthroughs and connect with directors and heads of informatics, molecular design, and data science.
Date and Time: On Monday March 09, 2026 at 8:30 am to Tuesday March 10, 2026 at 6:00 pm
Venue details: Hilton London Kensington, 179-199 Holland Park Avenue, London, England, W11 4UL, United Kingdom
The 6th TPD and Induced Proximity Summit Europe is the only European forum dedicated exclusively to proximity-based drug discovery. From PROTACs and molecular glues to stabilizers and extracellular degraders, this summit showcases the full spectrum of therapeutic innovation across oncology, neurodegeneration, immunology, and rare diseases. Held in London in March 2026, the event brings together more than 80 CxOs, directors, senior scientists and investors to accelerate proximity therapeutics from discovery to clinic.
Europe is experiencing a surge in strategic investment and innovation, including Sanofi’s acquisition of Blueprint Medicines for £7.2 billion and Merck’s £2.7 billion purchase of SpringWorks Therapeutics. As the region pivots toward non-oncology indications and novel mechanism…
Healthcare is changing faster than we can reactCompanies have had to make billion-dollar bets on AI, manufacturing, organizational models and CRM systems, going against decades of waiting for clarity before committing.
But clarity isn't coming, and patients can't wait. Nor can we.
It's time to stop predicting the future and prepare for all futures. What works across all of them? Patient-centricity and cross-functionality.
Cross-functionality unlocks trapped capabilities. Functional excellence without structural integration fails in today's efficiency-first world. When Medical and Commercial align, omnichannel delivers and launches accelerate. Coordination that consumed months compresses into days. World-class skills finally operate at world-class velocity, built on the technology stacks an…
Novel conjugates have become one of the most competitive and rapidly evolving areas in the precision oncology landscape. Companies are looking beyond traditional ADCs towards novel mechanism of action payloads and differentiated targeting formats for overcoming drug resistance, improved therapeutic windows and to make an impact in cancers which don’t respond to traditional ADCs, as well as the exploration of non-oncology indications.
The 5th Novel Conjugates Summit is the industry’s only dedicated meeting for an insider view into which novel approaches are currently being explored, what benefit each approach has and the directions the space is heading.
Attendees gain valuable competitive insight into emerging technologies, early data, and the rationale behind each approach, from establishe…
Want to hear what sector’s most influential thinkers say about where AI and next-gen therapies are heading in 2026?
AI is rapidly reshaping emerging biotech, advanced therapies and biologics in the UK. Machine learning now enables the analysis of large and complex datasets, supporting the discovery of new biomarkers and therapeutic targets and improving the modelling of biological responses. This leads to more precise and better targeted biologics and advanced therapies.
UK biotech organisations are also forming deeper partnerships with technology companies to access advanced data analytics and embed AI more effectively into research pipelines. Government backed initiatives are strengthening this progress and accelerating innovation.
AI driven drug repurposing is gaining momentum, helping…
The 8th CRISPR AgBio Congress is the leading forum for AgBiotech innovators, seed companies, growers, consumer food brands, and investors to accelerate the commercialization of gene-edited crops. With USDA easing regulatory pathways and AI revolutionizing trait discovery, now is the time to position your organization at the forefront of sustainable agriculture.
Join industry leaders, including Pairwise, Corteva, Bayer Crop Science, BASF, and more to explore next-generation CRISPR tools, AI-driven target discovery, and strategies for navigating global regulations.
New for 2026: Global Regulations and IP Focus Day, a dedicated Driving Consumer Acceptance Panel, and expanded sessions on AI applications in AgBio.
Be part of the only event combining technical breakthroughs with commercial know-…
The 11th Innate Killer Summit continues its legacy as the world's leading industry meeting dedicated exclusively to advancing NK and innate immune cell therapies.
This year, the summit unites pioneering biotechs, including NKGen, NKILT, Senti Bio, NKore, and leaders from the MD Anderson Rizvani Lab, alongside translational scientists and platform innovators to showcase breakthrough progress in engineering, manufacturing, persistence, tumor targeting, and clinical translation.
As the NK space becomes increasingly competitive and the path to differentiation narrows, this summit stands firmly alongside the global NK community, providing the clarity, collaboration, and momentum needed to keep innovation moving forward.
With in-depth scientific content, real-world clinical insights across six c…
Gene therapy is entering a defining new chapter. After a period of challenge and recalibration, the field is regaining momentum, driven by teams who remain steadfast in their belief that this science can transform lives. Confidence is returning, with significant investments and acquisitions signalling a renewed commitment to overcoming barriers of safety, efficacy, and scalability.
The 9th Gene Therapy Development Summit returns to Boston as the meeting point for this community. Join 100+ leading voices from the likes of Bayer, Astellas Pharmaceuticals, REGENXBIO, Ocugen, AskBio, CureDuchenne Ventures, and more to come together to share ideas, restore confidence, and chart a sustainable path forward for gene therapy.
Connect with your peers in pre-clinical development, manufacturing, analy…
CMAC Open Days 2026: Join us 24–26 March 2026 as we celebrate 15 years of CMAC transforming medicines manufacturing.
Discover how Industry 5.0 technologies are shaping the future of medicines manufacturing, with insights into the latest trends, tools, and strategies for creating future-ready, resilient and sustainable manufacturing processes.
At the Open Days you’ll:
🤝 Network with top academics, industry leaders, and researchers
👩🔬 Engage in interactive sessions, lab tours, and poster presentations
💊 Learn about the latest innovations tackling real-world pharmaceutical challenges
🎟️ Registration is now open! Take advantage of early bird rates available until Monday 2 February 2026:
£100 standard (rising to £125 after early bird)
£80 PhD student (rising to £90 after early bird)
To,
I have reached out to you as your research areas/products/services are related to our upcoming conference. Considering the same, our organizing committee would like to invite to be a part of it and you will be a great fit for our upcoming “World Congress on Advances in Applied Science and Engineering” held during 25-26 March 2026. at London, United Kingdom
The WASE 2026 aims to bring together leading researchers, academicians, industry professionals, and policymakers to share innovations, exchange ideas, and foster collaboration across a wide range of topics. We extend warm invitation to you and your organization to be a part of the conference as a Sponsors/Exhibitor/Speaker/Delegate.
Let me know your interest in the same, accordingly I will share y…
LNPs continue to dominate the spotlight in biopharma with three landmark acquisitions in the past six months, AbbVie/Capstan Therapeutics, Eli Lilly and Co/Verve Therapeutics and Bristol Myers Squibb/Orbital Therapeutics. Validating LNPs as a stand-out delivery vehicle for cell and gene therapies!
Returning to Boston in April 2026, the 5th LNP Formulation and Process Development Summit is an industry-led end-to-end meeting providing the latest scientific content to advance LNP development for a variety of payloads and therapeutic applications, from mRNA vaccines to next-generation cell and gene therapies. This is your one-stop shop to hear insights on LNP discovery, analytics, formulation, process development and large-scale manufacturing.
With 3 focused streams, Analytical Development and…
Neuroimmunology is entering a defining moment. With the $470M buyout of Vigil's TREM2 asset, Ventus' NLRP3 inhibitor in phase 2a, and promising phase 3 BTKi readouts from Sanofi and Roche, the field is beginning to show encouraging signs of clinical viability in targeting neuroinflammation. Now the real race begins. Uncovering the next wave of mechanisms, biomarkers, and translational strategies that will move beyond today's successes and unlock new therapeutic frontiers in neurodegeneration and neuroimmune-driven psychiatric disease.
The 8th Neuroimmunology Drug Development Summit is the industry's only meeting fully dedicated to advancing novel neuroinflammatory targets, uniquely bridging cutting-edge academic discovery with the practical lens of drug development. This year's expanded pr…
Thought Leader Texas is a premier gathering for executives, innovators, and industry leaders who want to stay ahead of fast-moving shifts in business, leadership, and organizational strategy. This summit brings together experts from across sectors to share fresh perspectives, practical insights, and proven approaches that help leaders navigate today’s most pressing challenges.
Through keynote talks, panel discussions, and interactive sessions, attendees will explore themes such as leadership development, talent and culture, operational excellence, technology adoption, and long-term strategic growth. Each session is designed to offer actionable takeaways-clear ideas and tools executives can bring back to their organizations.
The event also creates space for meaningful networking, allowing l…
The conference features a comprehensive pre-conference focus day dedicated to advancements in device design, followed by a dynamic two-day main conference featuring keynote plenaries, interactive panel discussions, and specialized topic streams covering the most pressing industry challenges and breakthrough solutions including:
Device Innovations for Large Volume and Novel Drug Product DeliveryAdvancing Sustainability in the Injectable Device IndustryPrimary Packaging: Ensuring Safe, Stable, and Biocompatible Combination ProductsPatient-Driven Device Design
Date and Time: Monday, 27 April 2026 at 08:30 - Wednesday, 29 April 2026 at 17:00
Optimizing ADC Physiochemical, Potency, and Impurity Analytical Methods to Enhance Product Understanding, Quality and Assess DARs for Regulatory Submissions
The 5th ADC Analytical Development Summit is the only dedicated platform for tackling the unique analytical complexities of ADC development, bringing together technical leaders to ensure a high-quality, regulatory-compliant ADC product.
The ADC landscape is undergoing a rapid transformation with novel modalities like bispecifics, dual payload conjugates, and novel conjugates all push the boundaries of innovation, whilst more traditional ADCs are progressing their way through the pipelines - analytical teams are facing greater challenges in ensuring product quality and regulatory compliance than ever. The 5th ADC Analytical Development…
Peptide therapies are rapidly becoming a disruptive modality, led by Merck’s oral PCSK9 inhibitor and Johnson and Johnson’s IL23R, with the hope to develop best-in-class drugs with improved chemistry, formulation and clinical efficacy.
To shine a light on the progress of this field, the highly anticipated 3rd Peptide-Based Therapeutics Summit returns to Boston as the industry’s only dedicated platform to turbocharge the next generation of peptide discoveries through development and towards life-saving treatments.
Gathering industry leaders including Parabilis Medicines, Circle Pharma, Abbvie, Merck, Chugai Pharmaceuticals and many more, this is your premium forum to explore:
- Novel computational tools- Optimize analytical assays- Formulating cell-specific delivery methods- DMPK translatab…
